Key of anticancer drug development, a matter of money or a matter of ideas?Both money and ideas are indispensable elements for anticancer drug developments and licensing. But money can be raised easier than Abstract Drug manufacture (highly competitive area) is pillar industry for many developed countries and largest medical expenditures worldwide. Nonetheless, new anticancer drug discovery, development and manufacture have been entering into bottleneck stages. The persistent reducing of successful rates of phase II and phase III anticancer drug evaluations in clinics are grim situations for most anticancer drug developers. Owing to all these undesired factors, anticancer drug developments are highly risky enterprising now. This editorial addresses important factors affecting anticancer drug developments in future. Me ta b o lo m ics: O p e n A c ce ss

to cytotoxic anticancer drugs often occurs in regrowed cancer cells. Yet cytotoxic anticancer drugs are good partner with most other types of anticancer (targeted agents), biotherapy or assistant therapies. 8. Combine anticancer drugs with cancer stem cell modulators or inhibitors; 9. Combine anticancer drugs by individualized or personalized evaluation and predictions of drug toxicity and responses etc.